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Synthesis and characterization of tetrasubstituted phenanthroline ligands: 
 
Compound 6b: A sealed vial containing 4 (50.0 mg, 0.085 mmol), NMP (4.5 mL) and NH3  (0.3 mL, 33% in 
H2O, 5.29 mmol) was heated in a microwave reactor at 175 °C for 16 hours to give a dark green mixture. 
Addition of MeCN (10 mL) followed by diethyl ether (30 mL) resulted in the precipitation of a yellow solid, 
which was isolated by centrifugation and washed with diethyl ether (2 mL) to give the crude product 6b 
(HPLC: 86% pure; 48.0 mg (88% yield)) as a brown solid, which was used in the synthesis of 7b without 
further purification.  
Compound 6c: A flask containing 4 (101 mg, 0.170 mmol) and pyrrolidine (4.9 mL, 59.4 mmol, 350 equiv.) 
was equipped with a reflux condenser and brought to a gentle reflux (87 °C) for 40 hours to afford a light 
yellow mixture with a yellow precipitate. The precipitate was isolated by centrifugation, and washed with 
H2O and diethyl ether to give 6c as an orange powder (102 mg, 90% yield). 1H NMR (400 MHz, 
[D6]DMSO) d = 11.73 (s, 2H), 9.65 (s, 2H), 9.04 (s, 2H), 8.28 (s, 2H), 8.13-7.92 (m, 4H), 7.72 (t, J = 7.9 Hz, 
2H), 7.69–7.60 (m, 4H), 3.94–3.77 (m, 8H), 2.15–2.00 (m, 8H). ESI-HRMS: calcd for C40H34N8O2Na+ 
(M+Na+): 681.2697, found: 681.2694. 
Compound 6d: A sealed vial containing 4 (50.0 mg, 0.085 mmol), NMP (1.5 mL) and methylamine (0.5 
mL, 33% in methanol, 4.02 mmol) was heated in a microwave reactor at 120 °C for 50 min to give an orange 
mixture with a precipitate. Dropwise addition of H2O (5 mL) resulted in additional precipitation. The 
precipitate was isolated by centrifugation and washed with H2O followed by ethanol and diethyl ether. 
Drying under vacuum gave 6d as an orange solid (42.3 mg, 85% yield). 1H NMR (400 MHz, [D6]DMSO) d 
= 11.73 (s, 2H), 9.66 (s, 2H), 9.06 (s, 2H), 8.27 (s, 2H), 8.06 (d, J = 6.8 Hz, 4H), 7.79 (d, J = 3.0 Hz, 2H), 
7.72 (t, J = 7.3 Hz, 2H), 7.64 (t, J = 7.3 Hz, 2H), 7.51 (s, 2H), 3.08 (d, J = 3.0 Hz, 6H). ESI-HRMS: calcd for 
C34H27N8O2+ (M+H+): 579.2251, found: 579.2224. 
Compound 6e: A sealed vial containing 4 (50.0 mg, 0.085 mmol), NMP (1.5 mL) and isopropylamine (0.37 
mL, 4.27 mmol) was heated in a microwave reactor at 140 °C for 3 hours to give an orange mixture with a 
precipitate. Dropwise addition of H2O (5 mL) resulted in additional precipitation. The precipitate was 
isolated by centrifugation and washed with H2O followed by ethanol and diethyl ether. Drying under vacuum 
gave 6e as an orange solid (46.7 mg, 86% yield). 1H NMR (400 MHz, [D6]DMSO) d = 11.74 (s, 2H), 9.66 (s, 
2H), 9.07 (s, 2H), 8.39 (s, 2H), 8.06 (t, J = 7.6 Hz, 4H), 7.73 (t, J = 7.4 Hz, 2H), 7.65 (t, J = 7.3 Hz, 2H), 
7.58 (s, 2H), 7.31 (d, J = 7.1 Hz, 2H), 4.14–4.00 (m, 2H), 1.41 (d, J = 6.1 Hz, 12H). ESI-HRMS: calcd for 
C38H35N8O2+ ([M+H]+): 635.2877, found: 635.2862. 
Ligand 6i: A sealed vial containing 4 (41.8 mg, 0.071 mmol) and diethylenetriamine (1.95 mL, 18.1 mmol) 
was heated in a microwave reactor at 80 °C for 35 min to give a clear orange mixture. Addition of MeCN (15 
mL) resulted in the precipitation of a yellow solid, which was isolated by centrifugation and washed with 
MeCN. The solid was redissolved in H2O (1 mL) and converted to its HCl salt by dropwise addition of HCl 
(4.0 M, aq.) until pH < 1. Addition of ethanol (3 mL) resulted in the precipitation of a yellow compound, 
which was isolated by centrifugation. The compound was crystallized from H2O/ethanol, washed with 
diethyl ether and dried under vacuum to give the HCl salt of 6i as a yellow powder (47.9 mg, 93% yield). 1H 
NMR (400 MHz, [D6]DMSO) d = 12.13 (s, 2H), 9.91 (s, 4H), 9.53 (s, 2H), 9.26 (br, 2H), 9.04 (s, 2H), 8.76 
(s, 2H), 8.39 (s, 6H), 8.08–7.98 (m, 4H), 7.81 (s, 2H), 7.75 (t, J = 7.5 Hz, 2H), 7.64 (t, J = 7.3 Hz, 2H), 4.12–
3.95 (m, 4H), 3.54 (m, 4H, merged with HDO), 3.41–3.36 (m, 4H), 3.33–3.26 (m, 4H). ESI-HRMS: calcd 
for C40H44N12O22+ ([M+2H]2+): 362.1850, found: 362.1849. 
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Ligand 6j: A sealed vial containing 4 (60.0 mg, 0.102 mmol) and N,N-dimethylethane-1,2-diamine (2.8 mL, 
25.6 mmol) was heated in a microwave reactor at 120 °C for 160 min to give a clear orange mixture. 
Addition of MeCN (12 mL) resulted in the precipitation of a yellow solid, which was isolated by 
centrifugation and washed with MeCN. The solid was redissolved in H2O (0.25 mL) and converted to its HCl 
salt by dropwise addition of HCl (4.0 M, aq.) until pH < 1. Addition of ethanol (1 mL) and diethyl ether (2 
mL) resulted in the precipitation of a yellow compound, which was isolated by centrifugation. Crystallization 
from H2O/ethanol and drying under vacuum afforded the HCl salt of 6j as a yellow powder (70.6 mg, 91% 
yield). 1H NMR (400 MHz, [D6]DMSO) d = 12.19 (s, 2H), 10.50 (s, 2H), 9.54 (d, J = 2.3 Hz, 2H), 9.23 (br, J 
= 3.3 Hz, 2H), 9.03 (d, J = 2.0 Hz, 2H), 8.76 (s, 2H), 8.03 (t, J = 8.9 Hz, 4H), 7.82 (s, 2H), 7.79–7.72 (m, 
2H), 7.68–7.62 (m, 2H), 4.14–4.02 (m, 4H), 3.65–3.60 (m, 4H), 2.95 (d, J = 4.6 Hz, 12H). ESI-HRMS: calcd 
for C40H41N10O2+ ([M+H]+): 693.3408, found: 693.3416. 
Ligand 6k: A sealed vial containing 4 (60.0 mg, 0.102 mmol), NMP (1.2 mL) and N,N,N'-trimethylethane-
1,2-diamine (0.67 mL, 5.13 mmol) was heated in a microwave reactor at 120 °C for 45 min to give a clear 
orange mixture. Addition of MeCN (12 mL) resulted in the precipitation of a yellow solid, which was 
isolated by centrifugation and washed with MeCN. The solid was redissolved in H2O (0.25 mL) and 
converted to its HCl salt by dropwise addition of HCl (4.0 M, aq.) until pH < 1. Addition of ethanol (1 mL) 
and diethyl ether (2 mL) resulted in the precipitation of a yellow compound, which was isolated by 
centrifugation. Crystallization from H2O/ethanol and drying under vacuum afforded the HCl salt of 6k as a 
yellow powder (72.3 mg, 89% yield). 1H NMR (400 MHz, [D6]DMSO) d = 12.07 (s, 2H), 10.72 (s, 2H), 9.65 
(d, J = 1.8 Hz, 2H), 9.12 (d, J = 1.9 Hz, 2H), 8.36 (s, 2H), 8.13 (s, 2H), 8.11–8.05 (m, 4H), 7.81–7.75 (m, 
2H), 7.72–7.66 (m, 2H), 4.05–3.92 (m, 4H), 3.68–3.62 (m, 4H), 3.35–3.32 (m, 6H), 2.93–2.80 (m, 12H). 
ESI-HRMS: calcd for C42H45N10O2+ ([M+H]+): 721.3721, found: 721.3721. 
Ligand 8b: A sealed vial containing 6g (60.1 mg, 0.081 mmol), DMF (2.0 mL), diisopropylethylamine (0.15 
mL, 0.859 mmol) and 1-amidinopyrazole hydrochloride (38.0 mg, 0.259 mmol) was heated in a microwave 
reactor at 100 °C for 90 min to give a clear dark yellow solution. Ethanol (8 mL) and diethyl ether (22 mL) 
was added to give a yellow precipitate, which was isolated by centrifugation and washed several times with 
ethanol (1 mL) + diethyl ether (2 mL). Drying under vacuum gave 8b as a yellow solid (58.8 mg, 88% 
yield). 1H NMR (400 MHz, [D6]DMSO) d = 11.73 (br, 2H), 9.62 (d, J = 1.4 Hz, 2H), 9.00 (s, 2H), 8.49 (s, 
2H), 8.08–8.02 (m, 4H), 8.01–7.97 (m, 2H), 7.82 (s, 2H), 7.73–7.68 (m, 2H), 7.64–7.59 (m, 2H), 7.52 (s, 
2H), 7.33 (br, 8H), 3.54–3.49 (m, 4H), 3.41–3.36 (m, 4H), 2.10–1.98 (m, 4H). 13C NMR (100 MHz, 
[D6]DMSO) d = 164.3, 157.1, 152.0, 149.3, 145.3, 144.8, 144.5, 132.6, 128.7, 128.1, 128.0, 127.9, 127.1, 
123.2, 119.4, 119.1, 98.6, 40.3, 38.8, 27.4. ESI-HRMS: calcd for C40H42N14O22+ (M2+): 375.1802, found: 
375.1815. 
Ligand 8c: A sealed vial containing 6h (29.6 mg, 0.039 mmol), DMF (1.0 mL), triethylamine (0.05 mL, 
0.359 mmol) and 1-amidinopyrazole hydrochloride (16.4 mg, 0.112 mmol) was heated in a microwave 
reactor at 100 °C for 90 min to give a clear yellow mixture. Addition of MeCN (8 mL) resulted in the 
precipitation of a yellow compound, which was isolated by centrifugation and washed with MeCN. Drying 
under vacuum gave 8c as a yellow powder (28.0 mg, 85% yield). 1H NMR (400 MHz, [D6]DMSO) d = 11.72 
(s, 2H), 9.63 (d, J = 2.2 Hz, 2H), 9.02 (d, J = 1.6 Hz, 2H), 8.45 (s, 2H), 8.10–7.97 (m, 4H), 7.97–7.87 (m, 
2H), 7.87–7.75 (m, 2H), 7.71 (t, J = 7.6 Hz, 2H), 7.62 (t, J = 7.5 Hz, 2H), 7.51 (s, 2H), 7.48–6.76 (m, 8H), 
3.32–3.20 (m, 4H), 1.96–1.77 (m, 4H), 1.77–1.58 (m, 4H). 13C NMR (100 MHz, [D6]DMSO) d = 164.4, 
157.1, 151.9, 149.3, 145.3, 144.9, 144.5, 132.6, 128.6, 128.1, 128.0, 127.9, 127.0, 123.2, 119.3, 119.1, 98.4, 
42.3, 40.6, 26.4, 25.0. ESI-HRMS: calcd for C42H46N14O22+ (M2+): 389.1959, found: 389.1977. 
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General procedure for quinoline N-methylation: A sealed vial containing the bisquinoline starting 
material (0.027-0.068 mmol, 1 equiv.), DMF (1.0 mL/0.035 mmol) and methyl iodide (11 equiv.) was heated 
in a microwave reactor at 115 °C for the specified time, to give an orange reaction mixture. Ethanol (4 mL) 
and diethyl ether (12 mL) was added to give an orange precipitate. The mixture was centrifuged and the 
solution was decanted, the precipitate was crystallized with H2O/MeCN/diethyl ether and the resulting 
yellow powder was washed with diethyl ether and dried under vacuum to give the desired compound as an 
iodide salt unless otherwise stated. 
Ligand 7b: Following the general procedure for quinoline N-methylation: Using crude 6b (48.0 mg, 0.065 
mmol) and heating in a microwave reactor at 115 °C for 2 hours provided 7b (42 mg, 60% yield after 2 
steps) as an orange powder after purification by HPLC (15-23.8% MeCN in H2O (0-7 min), Rt = 4.7 min). 1H 
NMR (400 MHz, [D6]DMSO) d = 12.38 (br, 2H), 10.19 (s, 2H), 9.68 (s, 2H), 8.60-8.07 (m, 8H), 8.00 (m, 
2H), 7.72 (s, 2H), 4.66 (s, 6H). 13C NMR (100 MHz, [D6]DMSO) d = 163.3, 155.2, 146.7, 145.1, 135.3, 
134.2, 133.8, 132.9, 130.2, 129.8, 129.1, 119.5, 119.0, 118.3, 104.4, 45.9. ESI-HRMS: calcd for 
C34H28N8O22+ (M2+): 290.1162, found: 290.1165. 
Ligand 7c: Following the general procedure for quinoline N-methylation: Using 6c (43.0 mg, 0.065 mmol) 
and heating in a microwave reactor at 115 °C for 90 min provided 7c as an orange powder (59 mg, 96% 
yield). 1H NMR (400 MHz, [D6]DMSO) d = 12.19 (br, 2H), 10.21 (s, 2H), 9.74 (s, 2H), 8.53 (d, J = 9.0 Hz, 
2H), 8.44 (d, J = 8.2 Hz, 2H), 8.38 (s, 2H), 8.23 (t, J = 7.6 Hz, 2H), 8.04 (t, J = 7.6 Hz, 2H), 7.69 (s, 2H), 
4.69 (s, 6H), 4.01–3.81 (m, 8H), 2.17–2.01 (m, 8H). 13C NMR (100 MHz, [D6]DMSO) d = 164.0, 153.4, 
146.4, 145.2, 135.3, 134.4, 133.9, 132.8, 130.2, 129.8, 129.0, 121.2, 119.9, 119.1, 103.5, 52.5, 46.2, 25.6. 
ESI-HRMS: calcd for C42H40N8O22+ (M2+): 344.1632, found: 344.1647. 
Ligand 7d: Following the general procedure for quinoline N-methylation: Using 6d (39.0 mg, 0.067 mmol) 
and heating in a microwave reactor at 115 °C for 75 min provided 7d as an orange powder (56.5 mg, 97% 
yield). 1H NMR (400 MHz, [D6]DMSO) d = 12.06 (br, 2H), 10.28 (s, 2H), 9.84 (s, 2H), 8.52 (d, J = 8.8 Hz, 
2H), 8.46 (d, J = 8.2 Hz, 2H), 8.34 (s, 2H), 8.23 (t, J = 7.8 Hz, 2H), 8.05 (t, J = 7.5 Hz, 2H), 7.97 (s, 2H), 
7.56 (s, 2H), 4.70 (s, 6H), 3.10 (d, J = 2.9 Hz, 6H). 13C NMR (100 MHz, [D6]DMSO) d = 164.7, 152.9, 
148.3, 145.8, 135.3, 134.5, 133.7, 133.0, 130.2, 129.9, 129.1, 119.3, 119.3, 119.2, 98.5, 45.9, 29.6. ESI-
HRMS: calcd for C36H32N8O22+ (M2+): 304.1319, found: 304.1310. 
Ligand 7e: Following the general procedure for quinoline N-methylation: Using 6e (43.2 mg, 0.068 mmol) 
and heating in a microwave reactor at 115 °C for 75 min provided 7e as an orange powder (57.9 mg, 93% 
yield). 1H NMR (400 MHz, [D6]DMSO) d = 12.09 (br, 2H), 10.29 (s, 2H), 9.84 (s, 2H), 8.53 (d, J = 8.9 Hz, 
2H), 8.50-8.38 (m, 4H), 8.23 (t, J = 7.8 Hz, 2H), 8.05 (t, J = 7.4 Hz, 2H), 7.63 (s, 2H), 7.50 (s, 2H), 4.70 (s, 
6H), 4.15-3.98 (m, 2H), 1.42 (d, J = 6.0 Hz, 12H). 13C NMR (100 MHz, [D6]DMSO) d = 164.6, 151.2, 148.1, 
145.7, 135.3, 134.5, 133.7, 133.0, 130.2, 129.9, 129.1, 119.4, 119.4, 119.2, 99.0, 45.9, 44.2, 21.8. ESI-
HRMS: calcd for C40H40N8O22+ (M2+): 332.1632, found: 332.1643. 
Ligand 7i: Following the general procedure for quinoline N-methylation: Using 6i (32.5 mg, 0.037 mmol) 
and heating in a microwave reactor at 115 °C for 75 min gave 7i as an orange powder (44.8 mg, 79% yield). 
1H NMR (400 MHz, [D6]DMSO) d = 12.10 (s, 2H), 10.25 (s, 2H), 9.82 (s, 2H), 9.33 (s, 2H), 8.54 (d, J = 9.0 
Hz, 2H), 8.46 (d, J = 7.9 Hz, 2H), 8.40 (s, 2H), 8.31 – 8.11 (m, 8H), 8.11 – 7.98 (m, 4H), 7.70 (s, 2H), 4.70 
(s, 6H), 3.89 – 3.82 (m, 4H), 3.68 – 3.33 (m, 8H, merged with HDO), 3.28 – 3.18 (m, 4H). 13C NMR (100 
MHz, [D6]DMSO) d = 164.4, 158.6, 152.0, 148.5, 145.7, 135.4, 134.5, 133.9, 133.0, 130.3, 129.9, 129.2, 
119.7, 119.2, 99.3, 46.0, 45.4, 44.2, 39.2(merged with DMSO), 35.3. ESI-HRMS: calcd for C42H48N12O22+ 
([M-4H]2+): 376.2006, found: 376.2020. 
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Ligand 7j: Following the general procedure for quinoline N-methylation: Using 6j (33.6 mg, 0.044 mmol) 
and heating in a microwave reactor at 125 °C for 16 hours. The resulting compound was crystallised in 
H2O/MeCN + 1% TFA to afford 7j as a TFA-salt (42.4 mg, 94% yield); orange powder. 1H NMR (400 MHz, 
[D6]DMSO) d = 12.20 (br, 2H), 10.28 (d, J = 1.7 Hz, 2H), 9.84 (s, 2H), 8.59–8.50 (m, 2H), 8.50–8.40 (m, 
4H), 8.31 (br, 2H), 8.26–8.18 (m, 2H), 8.11–7.99 (m, 2H), 7.75 (s, 2H), 4.71 (s, 6H), 4.10–4.01 (m, 4H), 
3.87–3.82 (m, 4H), 3.29 (s, 18H). 13C NMR (100 MHz, [D6]DMSO) d = 164.3, 151.8, 148.4, 145.7, 144.1, 
135.4, 134.4, 133.8, 133.0, 130.3, 129.9, 129.1, 119.8, 119.6, 119.2, 99.7, 62.7, 52.8, 46.0, 37.0. ESI-HRMS: 
calcd for C44H50N10O22+ ([M-2H]2+): 375.2054, found: 375.2067. 
Ligand 7k: Following the general procedure for quinoline N-methylation: Using 6k (33.6 mg, 0.044 mmol) 
and heating in a microwave reactor at 125 °C for 16 hours. The resulting compound was crystallised in 
H2O/MeCN + 1% TFA to afford  7k as a TFA-salt (48.8 mg, 93% yield); orange powder. 1H NMR (400 
MHz, [D6]DMSO) d = 12.16 (s, 2H), 10.30 (d, J = 1.8 Hz, 2H), 9.89 (d, J = 1.3 Hz, 2H), 8.59–8.48 (m, 4H), 
8.29–8.19 (m, 6H), 8.11–8.05 (m, 2H), 4.74 (s, 6H), 3.99–3.87 (m, 8H), 3.24 (s, 18H), 3.22 (s, 6H). 13C 
NMR (100 MHz, [D6]DMSO) d 164.1, 158.5, 148.4, 146.3, 145.9, 135.5, 134.7, 133.9, 132.8, 130.3, 130.0, 
129.2, 124.5, 123.0, 119.2, 109.7, 61.5, 52.7, 48.6, 46.1, 42.2. ESI-HRMS: calcd for C46H55N10O23+ ([M-
H]3+): 259.8164, found: 259.8175. 
Ligand 9b: Following the general procedure for quinoline N-methylation: Using 8b (21.1 mg, 0.026 mmol) 
and heating in a microwave reactor at 115 °C for 90 min gave 9b as an orange powder (27.3 mg, 83% yield). 
1H NMR (400 MHz, [D6]DMSO + 0.1% TFA) d = 12.17 (br, 2H), 10.24 (s, 2H), 9.79 (s, 2H), 8.53 (d, J = 8.9 
Hz, 2H), 8.50–8.41 (m, 4H), 8.29–8.19 (m, 2H), 8.11–7.98 (m, 4H), 7.64 (s, 2H), 7.37 (br, 8H), 4.70 (s, 6H), 
3.58–3.55 (m, 4H), 3.38–3.32 (m, 5H), 2.07–1.97 (m, 4H). 13C NMR (100 MHz, [D6]DMSO + 0.1% TFA) d 
= 164.3, 157.0, 152.5, 147.9, 145.5, 135.5, 134.5, 133.9, 132.9, 130.3, 129.9, 129.2, 119.5, 119.2, 99.2, 46.0, 
40.3, 38.7, 27.4. ESI-HRMS: calcd for C42H46N14O2 ([M-2H]2+): 389.1959, found: 389.1976. 
Ligand 9c: Following the general procedure for quinoline N-methylation: Using 8c (28.9 mg, 0.034 mmol) 
and heating in a microwave reactor at 115 °C for 75 min gave 9c as an orange powder (42.4 mg, 94% yield). 
1H NMR (400 MHz, [D6]DMSO + 0.1% TFA) d = 12.02 (br, 2H), 10.27 (s, 2H), 9.85 (s, 2H), 8.54 (d, J = 
8.9 Hz, 2H), 8.47 (d, J = 8.2 Hz, 2H), 8.43 (s, 2H), 8.25 (t, J = 7.8 Hz, 2H), 8.07 (t, J = 7.6 Hz, 2H), 7.81 (s, 
2H), 7.63 (s, 2H), 7.53–7.45 (m, 2H), 7.01 (br, 8H), 4.70 (s, 6H), 3.57–3.45 (m, 4H), 3.27–3.17 (m, 4H), 
1.90–1.76 (m, 4H), 1.76–1.63 (m, 4H). 13C NMR (100 MHz, [D6]DMSO + 0.1% TFA) d = 163.3, 157.0, 
153.3, 147.2, 145.1, 135.6, 134.5, 134.0, 132.8, 130.4, 129.9, 129.2, 119.6, 119.2, 118.8, 99.8, 46.1, 42.7, 
40.6, 26.3, 25.0. ESI-HRMS: calcd for C44H50N14O22+ ([M-2H]2+): 403.2115, found: 403.2132. 
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FRET melting data 
Table S1. Change in G4 melting temperatures, ? Tm, in the presence of ligands 1, 6f-k, 7a-k and 8-9a-c (0.4 
and 1.0 µM) determined from a FRET assay, using G4 oligonucleotides (0.2 µM) in lithium cacodylate buffer 
(10 µM, pH 7.3) containing KCl (10 mM) and LiCl (90 mM), and specificity (S) determined using a FRET 
competition assay. 
Ligand F21T[a]  Fckit2T[a]  FcmycT[a]  FdsT[a] 
 ? Tm [°C] 
at 0.4 µM 
? Tm [°C] at 
1.0 µM 
S[b]  ? Tm [°C] 
at 0.4 µM 
? Tm [°C] 
at 1.0 µM 
S[b]  ? Tm [°C] 
at 0.4 µM 
? Tm [°C] 
at 1.0 µM 
S[b]  ? Tm [°C] 
at 1.0 µM 
1 [d] 19.2[c] 0.95[c]  14.4 ±0.1 17.9 ±0.7 >0.95  10.2 ±1.0 16.9 ±0.8 >0.95  0.0 ±0.5 
6f 0.7 ±0.5 1.5 ±0.7    [d]  0.6 ±1.0 0.8 ±0.4 [d]  0.6 ±0.7 1.0 ±0.4 [d]  0.3 ±0.3 
6g -0.1 ±1.0 -0.2 ±0.9    [d]  0.2 ±0.4 1.3 ±0.8 [d]  0.3 ±1.0 0.7 ±0.8 [d]  0.5 ±0.2 
6h 1.3 ±0.4 1.2 ±0.8    [d]  1.3 ±0.5 1.2 ±0.5 [d]  0.0 ±0.2 0.1 ±0.3 [d]  0.4 ±0.4 
6i 0.4 ±0.6 -0.1 ±0.4    [d]  -0.2 ±0.5 0.3 ±0.6 [d]  0.2 ±0.7 0.3 ±0.6 [d]  0.5 ±0.3 
6j 0.6 ±0.9 0.6 ±0.6    [d]  1.4 ±0.9 1.9 ±0.8 [d]  0.5 ±0.7 0.8 ±1.0 [d]  -0.1 ±0.4 
6k 0.4 ±0.6 0.3 ±0.4    [d]  0.2 ±0.9 -0.2 ±0.9 [d]  0.4 ±0.5 0.9 ±0.7 [d]  -0.3 ±0.2 
7a 6.4 ±0.4 8.4 ±0.9 0.93  7.2 ±0.9 10.9 ±1.0 0.87  9.9 ±1.0 10.3 ±0.6 >0.95  -0.2 ±0.4 
7b 4.2 ±0.6 6.0 ±0.9 >0.95  5.2 ±0.2 7.2 ±0.5 0.94  7.5 ±0.8 11.7 ±1.0 >0.95  0.3 ±0.1 
7c 5.0 ±0.6 11.5±0.1 0.91  11.0 ±1.2 16.5 ±0.7 0.84  9.1 ±0.1 11.3 ±0.8 0.94  0.4 ±0.2 
7d 2.4 ±0.4 3.8±0.9    [d]  5.9 ±1.0 7.4 ±0.7 [d]  5.4 ±1.1 9.7 ±0.9 [d]  0.3 ±0.3 
7e 2.4 ±0.3 4.9±0.6    [d]  4.2 ±0.8 5.8 ±0.8 [d]  3.3 ±0.1 5.6 ±0.7 [d]  0.4 ±0.3 
7f 17.3 ±1.1 23.2 ±1.0 0.87  16.9 ±0.6 21.8 ±0.5 0.81  15.1 ±0.5 23.4 ±0.5 0.92  2.4 ±0.5 
7g 16.1 ±0.9 24.7 ±1.0 0.77  18.7 ±0.7 23.9 ±0.8 0.77  13.7 ±0.8 23.6 ±0.7 0.87  2.7 ±0.4 
7h 15.0 ±0.9 23.7 ±0.9 0.79  18.1 ±1.1 23.8 ±0.5 0.81  12.8 ±0.9 23.6 ±0.9 0.81  1.4 ±0.6 
7i 6.1 ±0.5 22.8 ±0.9 0.82  10.9 ±0.4 22.8 ±0.7 0.83  10.2 ±0.4 20.8 ±0.6 0.92  2.9 ±0.8 
7j 20.7 ±0.7 27.6 ±0.6 0.84  22.3 ±0.8 25.5 ±0.6 0.85  22.3 ±0.9 24.5 ±0.9 0.94  1.9 ±0.3 
7k 23.3 ±0.4 25.0 ±0.2 0.95  23.4 ±0.4 25.1 ±0.6 >0.95  22.8 ±0.7 24.7 ±0.4 >0.95  1.9 ±0.3 
8a 2.0 ±0.9 3.5 ±1.0    [d]  1.2 ±0.4 1.3 ±0.6 [d]  0.6 ±0.8 1.1 ±0.9 [d]  0.3 ±0.2 
8b 0.7 ±1.0 1.5 ±0.8    [d]  1.3 ±0.9 2.4 ±1.0 [d]  1.0 ±0.4 2.3 ±0.8 [d]  0.6 ±0.3 
8c 0.3 ±0.7 0.6 ±0.9    [d]  -0.4 ±0.4 -0.4 ±0.5 [d]  0.3 ±1.1 0.5 ±0.4 [d]  0.1 ±0.7 
9a 7.2 ±1.0 22.4 ±0.9 0.90  15.5 ±0.6 23.0 ±0.8 0.81  11.2 ±0.7 23.6 ±1.0 0.83  2.5 ±1.3 
9b 7.1 ±1.2 22.6 ±1.0 0.89  13.7 ±0.4 23.6 ±0.3 0.81  11.6 ±1.0 22.5 ±0.9 0.83  2.7 ±0.4 
9c 5.5 ±0.8 22.0 ±1.0 0.84  14.4 ±0.3 25.1 ±1.0 0.81  12.2 ±0.6 20.9 ±0.7 0.82  2.3 ±1.3 
[a] Melting temperatures in the absence of ligand: F21T (52.7 °C ± 1.0), Fckit2T (62.5 °C ± 1.0), FcmycT 
(64.4 °C ± 0.6) and FdsT (62.7 ± 0.9 °C). [b] S is the ratio of ligand-induced ? Tm of G4-DNA in the presence 
and absence of competitor ds26 (10µM). Selectivity experiments were performed with compounds exhibiting 
? Tm >10 °C. [c] Values reported by Gomez et al.1 [d] Not determined. 
                                                             
1 D. Gomez, A. Guédin, J.-L. Mergny, B. Salles, J.-F. o. Riou, M.-P. Teulade-Fichou, P. Calsou, Nucleic Acids Res. 
2010, 38, 7187-7198 
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FRET melting curves 
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Figure S1: FRET stabilization curves for compounds 7g and 9a at various concentrations (0-1.0 µM) upon 
binding to labeled G4 oligonucleotides F21T (black), ckit2 (red) and cmyc (blue). Buffer: Lithium 
cacodylate (10 mM, pH 7.3) with 10 mM KCl and 90 mM LiCl. 
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Fluorescent intercalator displacement (FID) curves 
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Figure S2: FID curves for ligands 1, 6g, 7c, 7g, 7j and 9a at various concentrations (0-2.5 µM) with 
sequences 22AG (black), ckit2 (red) and ds26(blue) at 0.25 µM DNA concentration in the presence of 100 
mM KCl and 10 mM lithium cacodylate buffer (pH 7.3). The thiazole orange (TO) concentration was 0.5 µM 
for 22AG and ckit2 and 0.75 µM for ds26. The TO displacement from ds26 could not be fitted to a regular 
displacement curve.
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Electrospray mass spectrometry (ESI-MS) 
To determine the Ka values of ligand binding to the human telomeric G-quadruplex 22AG, we recorded ESI-
MS spectra of mixtures of dT6 (2 µM), AG22 (5 µM) and ligand (2.5, 5 or 10 µM). The sample volume was 
100 µL, and all experiments were performed in triplicates. The reference was added to control that the areas 
of free and bound quadruplex was constant relative to the area of dT6 during measurements. The final charge 
distribution appears to be more dependant on the surface area of the ionized molecule than on the the 
location of each charge in solution [Rosu et al.].2 We have therefore assumed that the response factors of the 
free and bound DNA quadruplex are equal at the most abundant charge state (-5), so the peak areas (A) of 
this charge state was used to calculate the concentrations of free DNA (1:0), the 1:1 complex (1:1), the 1:2 
complex (1:2) and the free ligand (L), using the following formulae: 
Atot = A(1:0)5- + A(1:1)5- + A(1:2)5-  (1) 
[1:0] = 5 µM × A(1:0)5- / Atot  (2) 
[1:1] = 5 µM × A(1:1)5- / Atot  (3) 
[1:2] = 5 µM × A(1:2)5- / Atot  (4) 
[L]free = [L]tot – [1:1] – 2 × [2:1] (5) 
Ka,1 = [1:1] / ([L]free × [1:0])  (6) 
Ka,2 = [2:1] / ([L]free × [1:1])  (7) 
Typical spectra are shown in Figure S3. At ligand concentrations 2.5 and 5 µM only the free DNA and the 
1:1 complex was detectable, so the Ka,1 values reported in the main text are the average of the Ka,1-values 
obtained at these two ligand concentrations. At a ligand concentration of 10 µM, only the 1:1 and 2:1 
complexes were detectable, and so the Ka,2 values reported in the main text are the average of the results 
from measurements at this concentration. 
To determine the Ka-values of ligand binding to the duplex ds12, we recorded ESI-MS spectra of mixtures of 
dT6 (2 µM), ds12 duplex (5 µM) and ligand (10 µM). The sample volume was 100 µL, and all experiments 
were performed in triplicates. Only the 1:1 complex were observed in any significant amount, so only the 
Ka,1 value was calculated. An example spectrum is shown is Figure S4. 
                                                             
2 F. Rosu, E. De Pauw, V. Gabelica, Biochimie 2008, 90, 1074-1087. 
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Figure S3: Representative ESI-MS spectra of mixtures containing 5 µM telomeric G-quadruplex DNA 
(22AG), 2 µM reference dT6 and A) 2.5 µM 7g, B) 5 µM 7g, C) 10 µM 7g. The free DNA and its 1:1 and 1:2 
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complexes with 7g was detected primarily at charge states 4- and 5-. The most intense charge state (5-) was 
used for determining the Ka-values. 
 
Figure S4: Representative ESI-MS spectra of a mixture of 5 µM double stranded DNA (ds12), 2 µM 
reference dT6 and 10 µM 7g. The free DNA and its 1:1 complex with 7g was detected primarily at charge 
states 4- and 5-. The signal corresponding to the single strand at charge state 3- (ss123-) was also detected. 
The most intense charge state (5-) was used for determining the Ka,1-values.
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CD spectroscopy 
The effects of ligand binding on the folded conformation of 22AG and c-kit2 was investigated by real-time 
titrations of ligands 7g and 7k into pre-annealed solutions of the relevant G4-forming sequence in the 
absence or presence of K+ or Na+. See also Figure 4 of the main text. 
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Figure S5. CD spectra of titration experiments of ligand 7g (0-6 µM, 0-3 equiv.) in solutions of pre-annealed 
quadruplex DNA (2 µM) in Tris buffer (50 mM, pH 7.3) in the presence or absence of monovalent cations. 
A) Telomeric DNA (22AG) in the presence of NaCl (100 mM). B) 22AG in the absence of monovalent 
cations. C) 22AG in the presence of KCl (100 mM). D) c-kit2 in the absence of monovalent cations. 
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UV Vis spectrum of 7g and 7k 
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Figure S6: UV-Vis spectrum of 7g and 7k at 10 µM concentration in H2O. Both compounds exhibit local 
absorbtion maxima at around 238, 281 and 351 nm.
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Cytotoxicity dose-response curves: HT1080 and HeLa 
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Figure S7: Effect of ligands 1, 7g, 7j, 7k and 9a on A) HeLa cell viability and B) HT1080 cell viability. 
Cells were treated with varying concentrations of compounds (0–1 mM) in H2O (ligands 7g, 7j, 7k and 9a) or 
DMSO (1, from a 10 mM stock in DMSO; final DMSO concentration: up to 1 %) for 72 h.  
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NMR spectra of novel componds 6c-e,g,i-k, 7a-k and 8-9a-c  
1H-spectrum for 6c: 
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1H and COSY-spectra for 6e: 
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1H and COSY-spectra for 6g: 
N N
HN
O
NH
O
NN
NH HN
H3N NH3
2 Cl
19 
 
 
1H and COSY-spectra for 6i: 
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1H and COSY-spectra for 6j: 
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1H and COSY-spectra for 6k: 
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1H and 13C-spectra for 7b: 
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1H and 13C-spectra for 7c: 
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1H and 13C-spectra for 7d: 
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1H and 13C-spectra for 7e: 
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1H and 13C-spectra for 7g: 
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1H, COSY and 13C-spectra for 7i: 
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1H and 13C-spectra for 7j: 
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1H and 13C-spectra for 7k: 
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1H and 13C-spectra for 8a: 
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1H and 13C-spectra for 8b: 
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1H and 13C-spectra for 8c: 
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1H and 13C-spectra for 9a: 
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1H and 13C-spectra for 9b 
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1H and 13C-spectra for 9c 
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RP-HPLC profiles of ligand 6f-6k, 7a-k and 8-9a-c stock solutions  
Purity of stock solutions was analyzed by RP-HPLC using a Dionex 120 C18 column (5µ, 4.6x150 mm) 
using  1 mL min-1 flow, UV detection at 254 nm, and a gradient of 10 % MeCN in H2O (0-1 min), then 10-
100 % MeCN in H2O (1-11 min) followed by 100 % MeCN (11-15 min) with 0.05 % trifluoroacetic acid as 
modifier. The signal observed at Rt 2.0 min in the profiles is an artifact from the injection, and has been 
excluded from the purity calculations. 
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Ligand 6g: 
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Ligand 6i 
 
 
Ligand 6j 
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Ligand 6k 
 
 
Ligand 7a 
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Ligand 7b 
 
 
Ligand 7c 
 
 
N N
HN
O
NH
O
NN
N N
2 CF3COO
N N
HN
O
NH
O
NN
H2N NH2
2 CF3COO
42 
 
Ligand 7d 
 
 
Ligand 7e 
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Ligand 7f 
 
 
Ligand 7g 
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Ligand 7h 
 
 
Ligand 7i 
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Ligand 7j 
 
 
Ligand 7k 
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Ligand 8a 
 
 
Ligand 8b 
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Ligand 8c 
 
 
Ligand 9a 
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Ligand 9b 
 
 
Ligand 9c 
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